Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.

Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A.

Helicobacter. 2011 Dec;16(6):420-6. doi: 10.1111/j.1523-5378.2011.00867.x.

PMID:
22059392
2.

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.

Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L.

Dig Liver Dis. 2010 Feb;42(2):110-4. doi: 10.1016/j.dld.2009.05.013. Epub 2009 Oct 28.

PMID:
19846355
3.

Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.

Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS.

Helicobacter. 2009 Oct;14(5):77-85. doi: 10.1111/j.1523-5378.2009.00709.x.

PMID:
19751431
4.

Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.

Kang JM, Kim N, Lee DH, Park YS, Kim YR, Kim JS, Jung HC, Song IS.

Helicobacter. 2007 Dec;12(6):623-8.

PMID:
18001404
6.

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.

Nista EC, Candelli M, Zocco MA, Cazzato IA, Cremonini F, Ojetti V, Santoro M, Finizio R, Pignataro G, Cammarota G, Gasbarrini G, Gasbarrini A.

Aliment Pharmacol Ther. 2005 May 15;21(10):1241-7.

7.
8.

Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.

Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH.

Helicobacter. 2012 Jun;17(3):216-23. doi: 10.1111/j.1523-5378.2012.00937.x. Epub 2012 Mar 20.

PMID:
22515360
9.

Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.

Kiliç ZM, Köksal AS, Cakal B, Nadir I, Ozin YO, Kuran S, Sahin B.

Dig Dis Sci. 2008 Dec;53(12):3133-7. doi: 10.1007/s10620-008-0285-z. Epub 2008 May 9.

PMID:
18465244
10.

Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.

Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S.

J Clin Gastroenterol. 2013 Mar;47(3):228-32. doi: 10.1097/MCG.0b013e31826015b0.

PMID:
22858517
11.

New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain.

Schwarzer A, Urruzuno P, Iwańczak B, Martínez-Gómez MZ, Kalach N, Roma-Giannikou E, Liptay S, Bontem P, Buderus S, Wenzl TG, Koletzko S; ESPGHAN Working Group on Helicobacter pylori Infection..

J Pediatr Gastroenterol Nutr. 2011 Apr;52(4):424-8. doi: 10.1097/MPG.0b013e3181fc8c58.

PMID:
21407111
12.

The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.

Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.

Helicobacter. 2012 Oct;17(5):374-81. doi: 10.1111/j.1523-5378.2012.00960.x. Epub 2012 Jun 8.

PMID:
22967121
13.

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.

Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS.

Helicobacter. 2006 Feb;11(1):46-51.

PMID:
16423089
14.

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.

Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A.

Dig Liver Dis. 2009 Jul;41(7):480-5. doi: 10.1016/j.dld.2008.09.013. Epub 2008 Oct 30.

PMID:
18974025
15.

7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.

Antos D, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdörffer E.

Helicobacter. 2006 Feb;11(1):39-45.

PMID:
16423088
16.

Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.

Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS.

Helicobacter. 2010 Feb;15(1):38-45. doi: 10.1111/j.1523-5378.2009.00735.x.

PMID:
20302588
17.

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P.

Wien Klin Wochenschr. 2009;121(1-2):47-52. doi: 10.1007/s00508-008-1122-2.

PMID:
19263014
19.

Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.

Paoluzi OA, Visconti E, Andrei F, Tosti C, Lionetti R, Grasso E, Ranaldi R, Stroppa I, Pallone F.

J Clin Gastroenterol. 2010 Apr;44(4):261-6. doi: 10.1097/MCG.0b013e3181acebef.

PMID:
20195162
20.

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.

Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P.

Aliment Pharmacol Ther. 2002 Feb;16(2):315-24.

Supplemental Content

Support Center